KPIs & Operating Metrics(New)
Growth Metrics

Xylem (XYL) EBIAT (2016 - 2026)

Xylem has reported EBIAT over the past 17 years, most recently at $189.0 million for Q1 2026.

  • For Q1 2026, EBIAT rose 13.17% year-over-year to $189.0 million; the TTM value through Mar 2026 reached $974.0 million, up 7.74%, while the annual FY2025 figure was $950.0 million, 6.74% up from the prior year.
  • EBIAT for Q1 2026 was $189.0 million at Xylem, down from $333.0 million in the prior quarter.
  • Over five years, EBIAT peaked at $333.0 million in Q4 2025 and troughed at $82.0 million in Q1 2022.
  • A 5-year average of $181.3 million and a median of $167.0 million in 2025 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: dropped 17.86% in 2023 and later surged 110.87% in 2024.
  • Year by year, EBIAT stood at $149.0 million in 2022, then skyrocketed by 78.52% to $266.0 million in 2023, then grew by 22.56% to $326.0 million in 2024, then grew by 2.15% to $333.0 million in 2025, then plummeted by 43.24% to $189.0 million in 2026.
  • Business Quant data shows EBIAT for XYL at $189.0 million in Q1 2026, $333.0 million in Q4 2025, and $226.0 million in Q3 2025.